Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Funding This work was supported
2024-03-28

Funding This work was supported by Arena Pharmaceuticals, Inc, San Diego, CA, USA. Introduction 5-hydroxytryptamine 1B (5-HT1B) receptors are widely distributed in the central nervous system (CNS); they have various modulatory functions in drug reinforcement, appetitive behaviors, stress, moo
-
br Material and methods br
2024-03-28

Material and methods Results Discussion Clinical gene therapy trials with viral vectors have been in use for treatment of various genetic disorders and diseases, however efficacious, targetable and highly reliable non-viral delivery systems are needed for safe and long-term applications. De
-
br Conclusion br List of abbreviations br
2024-03-28

Conclusion List of abbreviations Acknowledgment The studies performed by our laboratory and presented in this review were supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan, (KAKENHI 17590618 [to H.I.] and KAKENHI 22249017 [to Y.Y.]), and the Japanese S
-
donepezil hydrochloride br Conclusion br Acknowledgments The
2024-03-28

Conclusion Acknowledgments The authors extend their appreciation to Kayyali Chair for Pharmaceutical Industry, Department of Pharmaceutics, College of Pharmacy, King Saud University for funding this work through the research project Number (G-2016-2). Introduction L-ornithine is a natural
-
Our research group has been involved
2024-03-27

Our research group has been involved by many years in the synthesis of new 2,3-benzodiazepin-4-ones (e.g. 1, Fig. 1) and in the characterization of their mechanism of action.15, 16, 17 Within the development of these compounds, we demonstrated that an improvement of AMPAR antagonism by 2,3-benzodiaz
-
A number of interesting anti inflammatory molecules
2024-03-27

A number of interesting anti-inflammatory molecules have also been identified that are derived from AA or ω−3 fatty acids, including the lipoxins (for “lipoxygenase interaction products”), resolvins, and protectins [18], [19] (Fig. 1). The lipoxins are synthesized from AA by 5-, 12-, and 15-LOX, as
-
Ketogenic diets are more effective in promoting weight loss
2024-03-27

Ketogenic diets are more effective in promoting weight loss than conventional caloric restriction [26] however, their effect on hepatic glucose and lipid metabolism remains inconclusive. Blood glucose homeostasis is tightly regulated. In both mice and humans consuming KD, baseline blood glucose decr
-
Mechanistically NAergic signaling in the VTA modulates
2024-03-27

Mechanistically, NAergic signaling in the VTA modulates neuronal activity presumably via α1-AR. The majority of α1-ARs are found in the VTA are located presynaptically on unmyelinated Anastrozole and axon terminals of glutamatergic and GABAergic neurons. However, α1-ARs are also found on neuronal de
-
Toxicity is the main reason for
2024-03-27

Toxicity is the main reason for the failure at all stages of the new drug development process. The major part of safety-related attrition occurs at preclinical phases while predicting preclinical safety liabilities earlier in the drug development process. This strategy enables the design and/or sele
-
For the NSCLC patients with
2024-03-27

For the NSCLC patients with EGFR-activating mutations, EGFR-TKIs (gefitinib and erlotinib) are effective clinical therapies [21], [22]. However, approximately 10% of patients harboring EGFR-sensitizing mutations exhibit intrinsic resistance, and up to 40% do not attain a major response to treatment
-
Pompe disease is accompanied by the deficiency of
2024-03-27

Pompe disease is accompanied by the deficiency of the lysosomal α-1,4-glucosidase that makes the PF-06447475 unable to hydrolyze glycogen to glucose, thereby resulting in the accumulation of glycogen in lysosomes, especially in skeletal muscles and cardiac tissues. This accumulation results in the
-
br Conflicts of interest br Introduction Phosphatidic acid p
2024-03-27

Conflicts of interest Introduction Phosphatidic enfuvirtide synthesis phosphatase (PAP) enzymes are responsible for catalyzing the reaction that dephosphorylates phosphatidic acid (PA), which in turn produces diacylglycerol (DAG) and a phosphate group during phospholipid regulation (Fig. 1A)
-
br Conclusions A large body of
2024-03-26

Conclusions A large body of evidence indicates that oxidative stress is involved in the pathogenesis of NDDs. Hence, reducing oxidative stress or suppressing its downstream pathways may be beneficial for the treatment of these diseases, especially such chronic diseases as AD or glaucoma. Here we
-
Over expression of the inflammatory cytokines
2024-03-26

Over expression of the inflammatory cytokines, MMPs and COX-2 act as an important inducer of chronic inflammation. COX-2 catalyzes the biosynthesis of prostaglandins (PGs), and induced expression was observed in Oprozomib stimulated with pro-inflammatory cytokines or bacterial lipopolysaccharide (K
-
Although sex hormones activational effects are known to dire
2024-03-26

Although sex hormones (activational effects) are known to directly interact with RAS (Baiardi et al., 2005, Miller et al., 1999, Silbiger and Neugarten, 1995), the potential contribution of organizational hormonal and SCC effects on physiological sex-based difference in the regulation of the RAS rem
16611 records 184/1108 page Previous Next First page 上5页 181182183184185 下5页 Last page